Clinical Trial Search

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276

Primary: Event-free Survival After 12 Months — 78 percentage of participants

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Event Free Survival (EFS) Per Blinded Central Assessment — 8.3; 2.0 months — p=<0.0001

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants

Primary: Overall Response Rate (ORR) — 48.3 percentage of participants

Primary: Progression Free Survival (PFS) — 6.6 months

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007) — 0 objective response

Primary: ORR — 13 Participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Progression-free Survival — 72 Percent

Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years

Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants

Primary: Objective Tumor Response — 0 participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants